There is one clinical trial.

Clinical Trials

1 Anticoagulation in Patients Suffering From COVID-19 Disease-The Anti-Co Trial

Patients with COVID-19 associated ARDS and mechanical ventilation have a high mortality. Part of the disease is an activation of the coagulation system which seems to contribute to clotformation in the pulmonary bloodstream. Recently we implemented an algorithm applying higher doses of heparins (LMWH). However, this approach could not inhibit clotformation enough. Bivalirudin could prevent clotformation better and support dissolving existing clots. Therefore, we want to compare 50 patients with the standard treatment with 50 patients under bivalirudin treatment which we normally apply in patients with a HIT-syndrome. Our primary outcome measure is oxygenation reflected as P/F ratio.

NCT04445935 Anticoagulation in COVID-19 ARDS Drug: Bivalirudin Injection Drug: Standard treatment

MeSH:Stress, Psychological

No related HPO nodes (Using clinical trials)